Related Experiment Videos
Model-based decision support in diabetes care.
E Salzsieder1, L Vogt, K-D Kohnert
1Institute of Diabetes "Gerhardt Katsch" Karlsburg, Greifswalder Str. 11e, D-17495 Karlsburg, Germany. salzsied@diabetes-karlsburg.de
Computer Methods and Programs in Biomedicine
|July 13, 2010
Summary
The Karlsburg Diabetes Management System (KADIS®) improves diabetes care by providing physicians with evidence-based recommendations. This patient-focused tool optimizes metabolic control through personalized, in silico simulations and clinical trials.
Area of Science:
- Medical Informatics
- Endocrinology
- Clinical Decision Support
Background:
- Diabetes management requires continuous optimization of metabolic control.
- Physicians need effective tools for individualized patient care.
- Existing systems may lack personalized, evidence-based decision support.
Purpose of the Study:
- To develop and evaluate the Karlsburg Diabetes Management System (KADIS®) as a decision-support tool.
- To assess KADIS®'s effectiveness in optimizing metabolic control for diabetes patients.
- To validate the system's utility in routine clinical practice.
Main Methods:
- Development of a model-based, patient-focused decision-support system (KADIS®).
- Implementation of personalized, in silico simulation procedures.
- Evaluation through open-label trials, a case-control study, and routine clinical application.
Main Results:
- KADIS® recommendations significantly improved metabolic control in diabetes patients.
- The system demonstrated effectiveness in guiding personalized treatment decisions.
- Successful integration and application in routine diabetes outpatient care.
Conclusions:
- The model-based KADIS® system effectively supports physicians in optimizing diabetes care.
- Personalized, evidence-based recommendations enhance metabolic control.
- KADIS® is a valuable tool for individualized diabetes management.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:26Diabetes Mellitus: Introduction
Diabetes mellitus consists of chronic metabolic disorders characterized by persistent hyperglycemia. This elevated blood glucose results from defects in insulin secretion, impaired insulin action, or both. Insulin, produced by pancreatic β-cells, is essential for maintaining glucose homeostasis by facilitating cellular glucose uptake for energy or storage. Disruptions in insulin production or function lead to glucose accumulation in the bloodstream, causing the clinical features and long-term...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).